Daiwa analyst Wilfred Yuen initiated coverage of BeiGene with a Buy rating and $308 price target. Brukinsa "looks poised to gain commercial success" given its best-in-class profile and upcoming key FDA approval in CLL, said Yuen, who believes BeiGene is "at the inflection point of a multi-year commercial story" with Brukinsa and tislelizumab.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BGNE:
- Fly Insider: Terns Pharma, Best Buy among week’s notable insider trades
- BeiGene announces CDE acceptance of tislelizumab sBLA
- BeiGene CEO sells $2.16M in common stock
- BeiGene says Brukinsa shows superior efficacy versus Imbruvica in study
- Phanes Therapeutics announces clinical supply agreement with BeiGene
